LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Elanco Animal Health Inc

Ouvert

SecteurSoins de santé

12.93 0.15

Résumé

Variation du prix de l'action

24h

Actuel

Min

12.78

Max

12.99

Chiffres clés

By Trading Economics

Revenu

75M

67M

Ventes

173M

1.2B

P/E

Moyenne du Secteur

17.093

56.602

BPA

0.37

Marge bénéficiaire

5.616

Employés

9,000

EBITDA

86M

261M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+13.06% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.6B

6.4B

Ouverture précédente

12.78

Clôture précédente

12.93

Sentiment de l'Actualité

By Acuity

50%

50%

173 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Elanco Animal Health Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 mai 2025, 11:29 UTC

Acquisitions, Fusions, Rachats

Elanco Sells Non-Core Asset to Blackstone for $295 Million

27 juin 2024, 14:34 UTC

Principaux Mouvements du Marché

Elanco Shares Retreat Over Zenrelia Warning Label Concerns

5 mai 2025, 11:14 UTC

Acquisitions, Fusions, Rachats

Elanco Sells Non-Core Asset to Blackstone for $295 Mln

5 mai 2025, 10:50 UTC

Acquisitions, Fusions, Rachats

Elanco Animal Health: Monetization of This Non-Core Asset Will Be Used to Accelerate Debt Reduction >ELAN

5 mai 2025, 10:49 UTC

Acquisitions, Fusions, Rachats

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone for $295M

9 juil. 2024, 12:30 UTC

Acquisitions, Fusions, Rachats

Merck Animal Health Completes Acquisition Of Elanco's Aqua Business >MRK

9 juil. 2024, 12:29 UTC

Acquisitions, Fusions, Rachats

Elanco Animal Health Sees Ending 2024 With Net Debt to Adjusted Ebitda in Mid-4x Range >ELAN

9 juil. 2024, 12:28 UTC

Acquisitions, Fusions, Rachats

Elanco Animal Health: $1.05B-$1.1B Net Proceeds Available for Debt Paydown in 3Q >ELAN

9 juil. 2024, 12:28 UTC

Acquisitions, Fusions, Rachats

Elanco Completes Sale of Aqua Business to Merck >ELAN MRK

Comparaison

Variation de prix

Elanco Animal Health Inc prévision

Objectif de Prix

By TipRanks

13.06% hausse

Prévisions sur 12 Mois

Moyen 14.63 USD  13.06%

Haut 20 USD

Bas 10 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

7

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

9.77 / N/ASupport & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bullish Evidence

Sentiment

By Acuity

173 / 382Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Elanco Animal Health Inc

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.